S&P 500   3,775.72 (-1.92%)
DOW   30,450.06 (-1.57%)
QQQ   323.97 (-1.41%)
AAPL   143.78 (+0.43%)
MSFT   235.11 (+1.20%)
FB   275.68 (-2.26%)
GOOGL   1,842.76 (-3.42%)
AMZN   3,282.84 (-1.30%)
TSLA   883.61 (+0.06%)
NVDA   522.40 (-2.79%)
BABA   262.86 (-1.15%)
CGC   38.27 (+7.74%)
GE   10.83 (-4.07%)
MU   76.65 (-3.60%)
AMD   90.93 (-3.99%)
NIO   58.06 (-3.73%)
T   29.26 (-1.65%)
F   10.86 (-2.95%)
ACB   11.54 (+8.15%)
BA   194.09 (-3.94%)
DIS   163.91 (-3.33%)
NFLX   537.33 (-4.38%)
GILD   65.67 (-1.54%)
S&P 500   3,775.72 (-1.92%)
DOW   30,450.06 (-1.57%)
QQQ   323.97 (-1.41%)
AAPL   143.78 (+0.43%)
MSFT   235.11 (+1.20%)
FB   275.68 (-2.26%)
GOOGL   1,842.76 (-3.42%)
AMZN   3,282.84 (-1.30%)
TSLA   883.61 (+0.06%)
NVDA   522.40 (-2.79%)
BABA   262.86 (-1.15%)
CGC   38.27 (+7.74%)
GE   10.83 (-4.07%)
MU   76.65 (-3.60%)
AMD   90.93 (-3.99%)
NIO   58.06 (-3.73%)
T   29.26 (-1.65%)
F   10.86 (-2.95%)
ACB   11.54 (+8.15%)
BA   194.09 (-3.94%)
DIS   163.91 (-3.33%)
NFLX   537.33 (-4.38%)
GILD   65.67 (-1.54%)
S&P 500   3,775.72 (-1.92%)
DOW   30,450.06 (-1.57%)
QQQ   323.97 (-1.41%)
AAPL   143.78 (+0.43%)
MSFT   235.11 (+1.20%)
FB   275.68 (-2.26%)
GOOGL   1,842.76 (-3.42%)
AMZN   3,282.84 (-1.30%)
TSLA   883.61 (+0.06%)
NVDA   522.40 (-2.79%)
BABA   262.86 (-1.15%)
CGC   38.27 (+7.74%)
GE   10.83 (-4.07%)
MU   76.65 (-3.60%)
AMD   90.93 (-3.99%)
NIO   58.06 (-3.73%)
T   29.26 (-1.65%)
F   10.86 (-2.95%)
ACB   11.54 (+8.15%)
BA   194.09 (-3.94%)
DIS   163.91 (-3.33%)
NFLX   537.33 (-4.38%)
GILD   65.67 (-1.54%)
S&P 500   3,775.72 (-1.92%)
DOW   30,450.06 (-1.57%)
QQQ   323.97 (-1.41%)
AAPL   143.78 (+0.43%)
MSFT   235.11 (+1.20%)
FB   275.68 (-2.26%)
GOOGL   1,842.76 (-3.42%)
AMZN   3,282.84 (-1.30%)
TSLA   883.61 (+0.06%)
NVDA   522.40 (-2.79%)
BABA   262.86 (-1.15%)
CGC   38.27 (+7.74%)
GE   10.83 (-4.07%)
MU   76.65 (-3.60%)
AMD   90.93 (-3.99%)
NIO   58.06 (-3.73%)
T   29.26 (-1.65%)
F   10.86 (-2.95%)
ACB   11.54 (+8.15%)
BA   194.09 (-3.94%)
DIS   163.91 (-3.33%)
NFLX   537.33 (-4.38%)
GILD   65.67 (-1.54%)
Log in
NASDAQ:FPRX

Five Prime Therapeutics News Headlines

$16.03
+0.86 (+5.67 %)
(As of 01/27/2021 02:09 PM ET)
Add
Compare
Today's Range
$14.24
Now: $16.03
$16.21
50-Day Range
$13.81
MA: $17.08
$20.10
52-Week Range
$1.75
Now: $16.03
$24.70
Volume64,493 shs
Average Volume1.15 million shs
Market Capitalization$609.75 million
P/E RatioN/A
Dividend YieldN/A
Beta4.4

Headlines

Five Prime Therapeutics (NASDAQ FPRX) News Headlines Today

Source:
SourceHeadline
Five Prime Therapeutics (NASDAQ:FPRX) Upgraded to Hold by Zacks Investment ResearchFive Prime Therapeutics (NASDAQ:FPRX) Upgraded to Hold by Zacks Investment Research
marketbeat.com - January 19 at 4:52 AM
Five Prime Therapeutics (NASDAQ:FPRX) Trading 7.1% Higher Five Prime Therapeutics (NASDAQ:FPRX) Trading 7.1% Higher
americanbankingnews.com - January 22 at 7:18 PM
Five Prime Therapeutics (NASDAQ:FPRX) Stock Price Down 6.8%Five Prime Therapeutics (NASDAQ:FPRX) Stock Price Down 6.8%
americanbankingnews.com - January 21 at 8:22 PM
Short Interest in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Expands By 26.8%Short Interest in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Expands By 26.8%
americanbankingnews.com - January 17 at 10:44 AM
Five Prime Therapeutics (NASDAQ:FPRX) Shares Gap Up to $15.96Five Prime Therapeutics (NASDAQ:FPRX) Shares Gap Up to $15.96
americanbankingnews.com - January 15 at 12:04 PM
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ CancersPhase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers
finance.yahoo.com - January 15 at 8:34 AM
Five Prime Therapeutics (NASDAQ:FPRX) Stock Price Up 6.7%Five Prime Therapeutics (NASDAQ:FPRX) Stock Price Up 6.7%
americanbankingnews.com - January 14 at 9:29 PM
Five Prime Therapeutics (NASDAQ:FPRX) Stock Price Down 7.6%Five Prime Therapeutics (NASDAQ:FPRX) Stock Price Down 7.6%
americanbankingnews.com - January 12 at 9:51 PM
Five Prime Therapeutics (NASDAQ:FPRX) Trading 5% Higher Five Prime Therapeutics (NASDAQ:FPRX) Trading 5% Higher
americanbankingnews.com - January 8 at 7:42 PM
Thinking about buying stock in Zomedica, Zosano Pharma, TapImmune, Five Prime Therapeutics, or Inuvo?Thinking about buying stock in Zomedica, Zosano Pharma, TapImmune, Five Prime Therapeutics, or Inuvo?
prnewswire.com - January 5 at 10:09 AM
Were Hopeful That Five Prime Therapeutics (NASDAQ:FPRX) Will Use Its Cash WiselyWe're Hopeful That Five Prime Therapeutics (NASDAQ:FPRX) Will Use Its Cash Wisely
finance.yahoo.com - December 21 at 9:31 AM
Is FPRX A Good Stock To Buy Now?Is FPRX A Good Stock To Buy Now?
finance.yahoo.com - December 18 at 12:38 AM
Five Prime Therapeutics: Understanding BemarituzumabFive Prime Therapeutics: Understanding Bemarituzumab
seekingalpha.com - December 11 at 10:27 PM
Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual SymposiumFive Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium
finance.yahoo.com - December 9 at 6:04 PM
Why Five Prime Therapeutics Stock Gained 312% in NovemberWhy Five Prime Therapeutics Stock Gained 312% in November
fool.com - December 8 at 10:08 AM
Five Prime Therapeutics: Primed For GrowthFive Prime Therapeutics: Primed For Growth
seekingalpha.com - December 4 at 9:01 AM
Five Prime Announces Closing of Upsized Public Offering of Common StockFive Prime Announces Closing of Upsized Public Offering of Common Stock
finance.yahoo.com - November 17 at 8:03 PM
Five Prime prices upsized equity offering at $21Five Prime prices upsized equity offering at $21
seekingalpha.com - November 13 at 7:44 AM
Why Five Prime Therapeutics Stock Is Trading Higher TodayWhy Five Prime Therapeutics Stock Is Trading Higher Today
benzinga.com - November 13 at 1:10 AM
Five Prime Announces Pricing of Upsized Public Offering of Common StockFive Prime Announces Pricing of Upsized Public Offering of Common Stock
finance.yahoo.com - November 13 at 1:10 AM
Small Biotech Five Prime Launches For A Second Day Running — Heres WhySmall Biotech Five Prime Launches For A Second Day Running — Here's Why
finance.yahoo.com - November 12 at 3:09 PM
Five Prime shares rise 14% as anti-CCR8 antibody FPA157 shows promising effectFive Prime shares rise 14% as anti-CCR8 antibody FPA157 shows promising effect
seekingalpha.com - November 12 at 10:09 AM
Are Options Traders Betting on a Big Move in Five Prime (FPRX) Stock?Are Options Traders Betting on a Big Move in Five Prime (FPRX) Stock?
finance.yahoo.com - November 12 at 10:09 AM
Is Five Prime Stock a Buy Right Now? This Is What You Need To KnowIs Five Prime Stock a Buy Right Now? This Is What You Need To Know
finance.yahoo.com - November 11 at 6:52 PM
Five Prime Announces Proposed Public Offering of Common StockFive Prime Announces Proposed Public Offering of Common Stock
finance.yahoo.com - November 11 at 6:52 PM
Why This Tiny Biotech Stock More Than Tripled In Bullish VolumeWhy This Tiny Biotech Stock More Than Tripled In Bullish Volume
finance.yahoo.com - November 11 at 6:52 PM
Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157
finance.yahoo.com - November 11 at 6:52 PM
ROCE Insights For Five Prime TherapeuticsROCE Insights For Five Prime Therapeutics
benzinga.com - November 11 at 1:51 PM
Five Primes Stock Quadruples On Positive Mid-Stage Stomach Cancer StudyFive Prime's Stock Quadruples On Positive Mid-Stage Stomach Cancer Study
msn.com - November 11 at 1:51 PM
Stock Alert: Five Prime Skyrockets 300% On Positive Results From Gastric Cancer Treatment TrialStock Alert: Five Prime Skyrockets 300% On Positive Results From Gastric Cancer Treatment Trial
nasdaq.com - November 11 at 1:51 PM
Five Prime soars 304% as bemarituzumab + chemo shows significant benefitFive Prime soars 304% as bemarituzumab + chemo shows significant benefit
seekingalpha.com - November 11 at 8:50 AM
Why Five Prime Therapeutics Stock Is on Fire TodayWhy Five Prime Therapeutics Stock Is on Fire Today
finance.yahoo.com - November 11 at 8:50 AM
Five Prime rockets 210% on bemarituzumab data in gastric cancerFive Prime rockets 210% on bemarituzumab data in gastric cancer
seekingalpha.com - November 10 at 7:54 PM
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction CancerFive Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
finance.yahoo.com - November 10 at 7:54 PM
Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction CancerZai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Cancer
finance.yahoo.com - November 10 at 7:54 PM
Heres What Analysts Are Forecasting For Five Prime Therapeutics, Inc. (NASDAQ:FPRX) After Its Third-Quarter ResultsHere's What Analysts Are Forecasting For Five Prime Therapeutics, Inc. (NASDAQ:FPRX) After Its Third-Quarter Results
finance.yahoo.com - November 6 at 11:46 AM
Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Earnings Call TranscriptFive Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 4 at 2:51 AM
Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Quick Version Earnings Call TranscriptFive Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Quick Version Earnings Call Transcript
seekingalpha.com - November 3 at 9:39 PM
Recap: Five Prime Therapeutics Q3 EarningsRecap: Five Prime Therapeutics Q3 Earnings
finance.yahoo.com - November 3 at 9:39 PM
Five Prime Therapeutics (FPRX) Reports Q3 Loss, Lags Revenue EstimatesFive Prime Therapeutics (FPRX) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 3 at 9:39 PM
Five Prime Therapeutics EPS misses by $0.15, misses on revenueFive Prime Therapeutics EPS misses by $0.15, misses on revenue
seekingalpha.com - November 3 at 4:39 PM
Five Prime Therapeutics, Inc. to Host Earnings CallFive Prime Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 3 at 4:39 PM
Five Prime Therapeutics Reports Third Quarter 2020 ResultsFive Prime Therapeutics Reports Third Quarter 2020 Results
finance.yahoo.com - November 3 at 4:39 PM
Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual MeetingFive Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting
finance.yahoo.com - November 2 at 10:51 PM
Will Five Prime Therapeutics (FPRX) Report Negative Q3 Earnings? What You Should KnowWill Five Prime Therapeutics (FPRX) Report Negative Q3 Earnings? What You Should Know
finance.yahoo.com - October 28 at 2:43 PM
Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference CallFive Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call
finance.yahoo.com - October 27 at 11:24 PM
Five Prime (FPRX) Looks Good: Stock Adds 5.1% in SessionFive Prime (FPRX) Looks Good: Stock Adds 5.1% in Session
nasdaq.com - October 12 at 4:48 PM
Five Prime Therapeutics Inc. Re (5P8.SG)Five Prime Therapeutics Inc. Re (5P8.SG)
au.finance.yahoo.com - October 9 at 12:43 PM
Five Prime Therapeutics, Inc. (FPRX)Five Prime Therapeutics, Inc. (FPRX)
finance.yahoo.com - October 1 at 12:00 PM
Five Prime Therapeutics (FPRX) Investor Presentation - SlideshowFive Prime Therapeutics (FPRX) Investor Presentation - Slideshow
seekingalpha.com - September 24 at 5:25 PM
Benzinga's Top Upgrades, Downgrades For September 22, 2020Benzinga's Top Upgrades, Downgrades For September 22, 2020
finance.yahoo.com - September 22 at 10:41 PM
This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.